A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to
placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial
seizures with or without secondary generalization despite current treatment with 1 or 2
concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in
subjects >= 16 years to 80 years of age.